Real-time Real Talk by Dexcom

Episode 1

EPISODE 1 – INTRODUCTION TO DEXCOM G6 CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM

Guest Speakers: Apurv Kamath, Senior VP, Marketing, Dexcom

Sushma Reddy, MD, Endocrinologist, Carbon Health

In this pilot episode we are going to talk about revolutionary technology in diabetes management brought to you by Dexcom. Continuous Glucose Monitoring, or CGM, has been around for nearly 2 decades and has improved the lives of thousands of people living with diabetes around the world. We will take a closer look at Dexcom G6 CGM System; what makes this product so innovative, and how clinicians use it in their practice.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to Dexcom G6 User guide. For product related questions, please refer to instructions for use. For complete safety information, go to dexcom.com/safety-information Smart devices are sold separately. For a list of compatible smart devices visit dexcom.com/compatibility 

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.

The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older.

The Hello Dexcom experience is a no-cost sampling program that helps introduce you and your patients to the features and benefits of Dexcom G6, while offering actionable insights that can inform your treatment decisions.

Dexcom G6 System User Guide

Safety Information https://www.dexcom.com/safety-information

Connectivity – basics (https://provider.dexcom.com/dexcom-cgm/collaborators)

Sensor Insertion process (https://provider.dexcom.com/education-research/cgm-education-use)

About Dexcom. https://www.dexcom.com/about-Dexcom

 

Brief Safety Statement

Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

The web-based Dexcom CLARITY software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.

Dexcom, Dexcom Follow, Dexcom CLARITY, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

 

References:

1. American Diabetes Association Professional Practice Committee; 7. Diabetes Technology:Standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1): S97–S112. https://doi.org/10.2337/dc22-S007

 

2. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. 2017;317(4):371–378. doi:10.1001/jama.2016.19975

 

3. Welsh JB, Gao P, Derdzinski M, Puhr S, Johnson TK, Walker TC, Graham C. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther. 2019 Mar;21(3):128-132. doi: 10.1089/dia.2018.0374. Epub 2019 Jan 25. PMID: 30681379; PMCID: PMC6434583.

 

4. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. 2017;317(4):379–387. doi:10.1001/jama.2016.19976

 

5. William H. Polonsky and Addie L. Fortmann. Impact of Real-Time Continuous Glucose Monitoring Data Sharing on Quality of Life and Health Outcomes in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics.Mar 2021.195-202.http://doi.org/10.1089/dia.2020.0466

 

6. Welsh, J.B., Derdzinski, M., Parker, A.S. et al.Real-Time Sharing and Following of Continuous Glucose Monitoring Data in Youth. Diabetes Ther 10, 751–755 (2019). https://doi.org/10.1007/s13300-019-0571-0

 

7. Welsh JB, Zhang X, Puhr SA, et al. Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes.Journal of Diabetes Science and Technology. 2019;13(2):254-258. doi:1177/1932296818798816

 

8. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444

 

9. Shah V LL, Wadwa P, et al. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technology and Therapeutics. 2018;20(6)

 

10. Klonoff DC, Parkes JL, Kovatchev BP, Kerr D, Bevier WC, Brazg RL, Christiansen M, Bailey TS, Nichols JH, Kohn MA. Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. Diabetes Care. 2018 Aug;41(8):1681-1688. doi: 10.2337/dc17-1960. Epub 2018 Jun 13. PMID: 29898901.

 

11. Hirose T, Mita T, Fujitani Y, Kawamori R, Watada H. Glucose monitoring after fruit peeling: pseudohyperglycemia when neglecting hand washing before fingertip blood sampling: wash your hands with tap water before you check blood glucose level. Diabetes Care. 2011 Mar;34(3):596-7. doi: 10.2337/dc10-1705. Epub 2011 Jan 31. PMID: 21282342; PMCID: PMC3041187.

 

12. Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018 Jun;20(6):428-433. doi: 10.1089/dia.2018.0143. PMID: 29923775; PMCID: PMC6422005.